Sinopharm's China National Biotec Group (CNBG) has administered more than 4 million COVID-19 vaccine doses as of January 4 via China's emergency use program, as reported in the National Post.
Two vaccines respectively from two institutes owned by CNBG are included in China’s emergency vaccination scheme, which was officially started in July targeting specific groups of people facing a high infection risk.
"No serious adverse reaction was reported in large-scale emergency use of Sinopharm's COVID-19 vaccines," CNBG said.
The company noted that a total of 72,000 people have been overseas after receiving China's emergency jabs, including around 40% of more than 5000 staffers on one Chinese firm's Pakistan-based project.
To read more NewsPoints articles, click here.